Literature DB >> 31383963

Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features.

Priyadharsini Nagarajan1, Jin Piao2,3, Jing Ning3, Laura E Noordenbos4,5, Jonathan L Curry6,7, Carlos A Torres-Cabala6,7, A Hafeez Diwan8, Doina Ivan6,7, Phyu P Aung6, Merrick I Ross4, Richard E Royal4, Jennifer A Wargo4, Wei-Lien Wang6, Rashmi Samdani6, Alexander J Lazar6,9, Asif Rashid6, Michael A Davies9,10,11, Victor G Prieto6,7,9, Jeffrey E Gershenwald4,12, Michael T Tetzlaff13,14.   

Abstract

Pathological staging of primary anorectal mucosal melanoma is often performed according to the American Joint Commission on Cancer (AJCC) guidelines for cutaneous melanoma, as an anorectal melanoma-specific staging system does not exist. However, it remains unknown whether prognostic factors derived for cutaneous melanoma also stratify risk in anorectal melanoma. We retrospectively determined correlations between clinicopathological parameters and disease-specific survival in 160 patients. Patients were grouped by clinical stage at presentation (localized disease, regional or distant metastases). Cox proportional hazards regression models determined associations with disease-specific survival. We also summarized the somatic mutations identified in a subset of tumors analyzed for hotspot mutations in cancer-associated gene panels. Most of the patients were white (82%) and female (61%). The median age was 62 years. With a median follow-up of 1.63 years, median disease-specific survival was 1.75 years, and 121 patients (76%) died of anorectal melanoma. Patients presenting with regional (34%) or distant metastases (24%) had significantly shorter disease-specific survival compared to those with disease localized to the anorectum (42%). Of the 71 anorectal melanoma tumors analyzed for hotspot genetic alterations, somatic mutations involving the KIT gene (24%) were most common followed by NRAS (19%). Increasing primary tumor thickness, lymphovascular invasion, and absence of regression also correlated with shorter disease-specific survival. Primary tumor parameters correlated with shorter disease-specific survival in patients presenting with localized disease (tumor thickness) or regional metastases (tumor thickness, absence of regression, and lymphovascular invasion), but not in patients presenting with distant metastases. Grouping of patients according to a schema based on modifications of the 8th edition AJCC cutaneous melanoma staging system stratified survival in anorectal melanoma. Our findings support stage-specific associations between primary tumor parameters and disease-specific survival in anorectal melanoma. Moreover, the AJCC cutaneous melanoma staging system and minor modifications of it predicted survival among anorectal melanoma patients.

Entities:  

Mesh:

Year:  2019        PMID: 31383963     DOI: 10.1038/s41379-019-0340-7

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  43 in total

1.  KIT genetic alterations in anorectal melanomas.

Authors:  Raffaella Santi; Lisa Simi; Rossella Fucci; Milena Paglierani; Monica Pepi; Pamela Pinzani; Barbara Merelli; Marco Santucci; Gerardo Botti; Carmelo Urso; Daniela Massi
Journal:  J Clin Pathol       Date:  2014-11-14       Impact factor: 3.411

2.  Identification of recurrent mutational events in anorectal melanoma.

Authors:  Hui Min Yang; Susan J Hsiao; David F Schaeffer; Chi Lai; Helen E Remotti; David Horst; Mahesh M Mansukhani; Basil A Horst
Journal:  Mod Pathol       Date:  2016-10-14       Impact factor: 7.842

3.  Clinicopathologic Presentation and Natural History of Anorectal Melanoma: A Case Series of 18 Patients.

Authors:  Caitlin W Hicks; Emmanouil P Pappou; Jonathan T Magruder; Benny Gazer; Sandy Fang; Elizabeth C Wick; Susan L Gearhart; Nita Ahuja; Jonathan E Efron
Journal:  JAMA Surg       Date:  2014-06       Impact factor: 14.766

4.  Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma: a 20-year experience.

Authors:  Patrick Kelly; Gunar K Zagars; Jancie N Cormier; Merrick I Ross; B Ashleigh Guadagnolo
Journal:  Cancer       Date:  2011-03-28       Impact factor: 6.860

5.  Comparison of molecular abnormalities in vulvar and vaginal melanomas.

Authors:  Sebastian Aulmann; Hans P Sinn; Roland Penzel; C Blake Gilks; Sarah Schott; Jessica C Hassel; Dietmar Schmidt; Friedrich Kommoss; Peter Schirmacher; Stefan Kommoss
Journal:  Mod Pathol       Date:  2014-03-07       Impact factor: 7.842

6.  Treatment Strategies and Survival Trends for Anorectal Melanoma: Is it Time for a Change?

Authors:  James P Taylor; Miloslawa Stem; David Yu; Sophia Y Chen; Sandy H Fang; Susan L Gearhart; Bashar Safar; Jonathan E Efron
Journal:  World J Surg       Date:  2019-07       Impact factor: 3.352

7.  Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma.

Authors:  Markus V Heppt; Alexander Roesch; Benjamin Weide; Ralf Gutzmer; Friedegund Meier; Carmen Loquai; Katharina C Kähler; Anja Gesierich; Markus Meissner; Dagmar von Bubnoff; Daniela Göppner; Max Schlaak; Claudia Pföhler; Jochen Utikal; Lucie Heinzerling; Ioana Cosgarea; Jutta Engel; Renate Eckel; Alexander Martens; Laura Mirlach; Imke Satzger; Gabriele Schubert-Fritschle; Julia K Tietze; Carola Berking
Journal:  Eur J Cancer       Date:  2017-06-07       Impact factor: 9.162

8.  Epidemiology of Anorectal Melanoma in the United States: 1992 to 2011.

Authors:  Adrienne Callahan; William F Anderson; Sital Patel; Jill S Barnholtz-Sloan; Jeremy S Bordeaux; Margaret A Tucker; Meg R Gerstenblith
Journal:  Dermatol Surg       Date:  2016-01       Impact factor: 3.398

9.  Primary ano-rectal malignant melanomas within a population-based national patient series in Sweden during 40 years.

Authors:  Boel K Ragnarsson-Olding; Per J Nilsson; Lars B Olding; Bo R Nilsson
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

10.  Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics.

Authors:  Kathleen A Cronin; Andrew J Lake; Susan Scott; Recinda L Sherman; Anne-Michelle Noone; Nadia Howlader; S Jane Henley; Robert N Anderson; Albert U Firth; Jiemin Ma; Betsy A Kohler; Ahmedin Jemal
Journal:  Cancer       Date:  2018-05-22       Impact factor: 6.860

View more
  5 in total

1.  Distribution pattern of tumor infiltrating lymphocytes and tumor microenvironment composition as prognostic indicators in anorectal malignant melanoma.

Authors:  So-Woon Kim; Young Il Kim; Bilal Mustafa; Mi-Ju Kim; Gowun Jeong; Sung-Min Ahn; Seok-Byung Lim; Chang Sik Yu; Jin Cheon Kim; Seung-Mo Hong; In Ja Park
Journal:  Mod Pathol       Date:  2020-07-24       Impact factor: 7.842

2.  Treatment outcomes and prognostic factors in 47 patients with primary anorectal malignant melanoma in the immune therapy era.

Authors:  Dai Ogata; Keita Tsutsui; Kenjiro Namikawa; Konosuke Moritani; Kenta Nakama; Shunichi Jinnai; Akira Takahashi; Shunsuke Tsukamoto; Yukihide Kanemitsu; Naoya Yamazaki
Journal:  J Cancer Res Clin Oncol       Date:  2022-02-03       Impact factor: 4.553

3.  Post-Immunotherapy Robotic-Assisted Resection for Primary Anorectal Melanoma: A Case Report.

Authors:  Keita Tsutsui; Dai Ogata; Shunsuke Tsukamoto; Konosuke Moritani; Taisuke Mori; Kenjiro Namikawa; Akira Takahashi; Yukihide Kanemitsu; Naoya Yamazaki
Journal:  Case Rep Oncol       Date:  2022-02-07

Review 4.  Nerve Density and Neuronal Biomarkers in Cancer.

Authors:  Shahrukh R Ali; Madeleine Jordan; Priyadharsini Nagarajan; Moran Amit
Journal:  Cancers (Basel)       Date:  2022-10-01       Impact factor: 6.575

5.  Genetic alteration of Chinese patients with rectal mucosal melanoma.

Authors:  Huan Li; Lujing Yang; Yumei Lai; Xintong Wang; Xinyin Han; Siyao Liu; Dongliang Wang; Xiaojuan Li; Nana Hu; Yan Kong; Lu Si; Zhongwu Li
Journal:  BMC Cancer       Date:  2021-05-27       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.